fda warning letters compounded semaglutide tirzepatide 2025 altRx GLP-1 Review 2026: Updated for the Latest FDA Compounded Semaglutide Action - Pricing, Refund Policy, and What's Changing

Lilly, Novo, Hims Get FDA Warnings About Misleading Drug Communications

27.36

★★★★☆4.8 (126)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

28.75

★★★★★4.9 (98)

Why the FDA Issued 30 Warning Letters to Telehealth Sites Marketing Compounded GLP-1s

19.99

★★★★★5.0 (157)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

26.03

★★★★★4.7 (84)

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

21.93

★★★★★4.9 (203)

September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA – Partnership for Safe Medicines

21.97

★★★★★5.0 (176)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

29.59

★★★★★4.8 (132)